Tetra Therapeutics

On March 17, 1878, on his 24th birthday, he became independent and founded the drugstore "Shiono Gisaburo Shoten" at 3-12 Dojima-machi, Osaka.

Eight years after founding, in 1886, Western medicine began to spread widely, and imported Western medicines started to be sold.

In 1909, Gizo's second son, Chojiro, graduated from the Department of Pharmacology at the University of Tokyo, and SHIONOGI began full-scale pharmaceutical research. Chojiro started trial manufacturing, and the stomach acid suppressant "Antaciden," which was successfully commercialized, became the first new drug developed in-house by Shiono Gisaburo Shoten.

In 1909, the balance mark was registered as a trademark. The symbol of SHIONOGI is derived from the "balance" used to measure medicine, symbolizing accuracy, honesty, and trust.

In 1910, a pharmaceutical factory, "Shiono Pharmaceutical Factory," was newly built in Nishinari District, Osaka Prefecture, and started full-scale operation in 1910.

In 1943, the company name was changed to Shiono Giyaku Co., Ltd.

In 1945, due to rapid inflation and soaring prices after the end of the war, SHIONOGI was almost bankrupt and fell into the worst management condition since its founding.

In 1950, the painkiller "Cedes" was launched.

In 2011, acquired Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited.

In 2012, established Shionogi Limited, a development subsidiary, in the UK.

In 2014, with the vision of growing as a drug discovery-oriented pharmaceutical company, set ROE as one of the management indicators, clarified the items to be achieved over the past three years, and clearly indicated efforts toward the management goal of 2020 while reviewing results and issues annually in a rolling manner.

Establishment of a joint venture company with Shimadzu Corporation, "AdvanSentinel Inc."

Establishment of the general incorporated foundation, "Shionogi Infectious Disease Research Promotion Foundation"

Development of the SHIONOGI group brand and the establishment of the group brand mark

Establishment of Yui Connection Inc.

Launch of the COVID-19 treatment drug "Zocova"